ZFIN ID: ZDB-FISH-150901-11309
Fish name: nt11Tg
Genotype: nt11Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by nt11Tg
No data available
GENE EXPRESSION
Gene expression in nt11Tg
RNA expression
Expressed Gene Structure Conditions Figures
ascl1a standard conditions Fig. 1 with imageFig. 4 with image from Ramachandran et al., 2011
physical alteration: anatomical structure Fig. 1 from Conner et al., 2014
dkk1a standard conditions Fig. 1 with image from Ramachandran et al., 2011
dkk1b standard conditions Fig. 1 with image from Ramachandran et al., 2011
dkk2 standard conditions Fig. 1 with image from Ramachandran et al., 2011
dkk3a standard conditions Fig. 1 with image from Ramachandran et al., 2011
dkk3b standard conditions Fig. 1 with image from Ramachandran et al., 2011
fzd2 standard conditions Fig. 1 with imageFig. 2 with imageFig. 4 with image from Ramachandran et al., 2011
fzd3a standard conditions Fig. 1 with image from Ramachandran et al., 2011
fzd8a standard conditions Fig. 1 with image from Ramachandran et al., 2011
fzd8b standard conditions Fig. 1 with image from Ramachandran et al., 2011
fzd9a standard conditions Fig. 1 with image from Ramachandran et al., 2011
gapdh standard conditions Fig. 1 with image from Ramachandran et al., 2011
lin28a standard conditions Fig. 4 with image from Ramachandran et al., 2011
myca standard conditions Fig. 4 with image from Ramachandran et al., 2011
pax6a standard conditions Fig. 4 with image from Ramachandran et al., 2011
stat3 control Fig. 5 from Conner et al., 2014
chemical treatment: drug Fig. 5 from Conner et al., 2014
wnt2 standard conditions Fig. 1 with image from Ramachandran et al., 2011
wnt2ba standard conditions Fig. 1 with image from Ramachandran et al., 2011
wnt3 standard conditions Fig. 1 with image from Ramachandran et al., 2011
wnt4 standard conditions Fig. 1 with imageFig. 2 with imageFig. 4 with image from Ramachandran et al., 2011
wnt8b standard conditions Fig. 1 with imageFig. 2 with image from Ramachandran et al., 2011
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-opn1mw1 standard conditions Fig. 5 with image from Yin et al., 2012
Ab1-ascl1 ascl1a physical alteration: anatomical structure Fig. 1 from Conner et al., 2014
Ab3-stat3 stat3 control Fig. 5 from Conner et al., 2014
Ab3-stat3 chemical treatment: drug Fig. 5 from Conner et al., 2014
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions Fig. 4Fig. 5Fig. 8 from Conner et al., 2014
Fig. 5 with image from Yin et al., 2012
chemical treatment: pharmaceutical Fig. 4Fig. 5Fig. 8 from Conner et al., 2014
Fig. 1 from Sun et al., 2014
physical alteration: anatomical structure Fig. 1 from Conner et al., 2014
PHENOTYPE
Phenotype in nt11Tg
Phenotype Conditions Figures
Muller cell proliferative, abnormal chemical treatment: drug Fig. 5Fig. 8 from Conner et al., 2014
Muller cell proliferative, abnormal chemical treatment: purpurogallin, chemical treatment: double-stranded DNA fragment Fig. 8 from Conner et al., 2014
Muller cell proliferative, abnormal chemical treatment: pharmaceutical Fig. 8 from Conner et al., 2014
Muller cell proliferative, abnormal physical alteration: anatomical structure, chemical treatment: purpurogallin Fig. 1 from Conner et al., 2014
Muller cell cell population proliferation increased process quality, abnormal chemical treatment: pharmaceutical Fig. 1 from Sun et al., 2014
Muller cell receptor signaling pathway via JAK-STAT increased occurrence, abnormal chemical treatment: drug Fig. 5 from Conner et al., 2014
retinal inner nuclear layer cell population proliferation increased occurrence, abnormal chemical treatment: drug Fig. 5Fig. 8 from Conner et al., 2014
retinal inner nuclear layer cell population proliferation increased occurrence, abnormal chemical treatment: pharmaceutical Fig. 8 from Conner et al., 2014
retinal inner nuclear layer cell population proliferation increased occurrence, abnormal chemical treatment: purpurogallin, chemical treatment: double-stranded DNA fragment Fig. 8 from Conner et al., 2014
retinal outer nuclear layer cell population proliferation increased process quality, abnormal chemical treatment: pharmaceutical Fig. 1 from Sun et al., 2014

CITATIONS  (13)